Dr. Jeffrey L. Cummings

Research Professor, Department of Brain Health
Director, Chambers-Grundy Center for Transformative Neuroscience at UNLV
Expertise: Neuroscience, Neurodegenerative diseases, Alzheimer’s disease, Drug development, Clinical trials, Neurotherapeutics

Biography

UNLV research professor Jeffrey L. Cummings is a neurologist globally recognized for his contributions to Alzheimer's research, drug development, and clinical trials. He serves as the Joy Chambers-Grundy professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience at the Kirk Kerkorian School of Medicine's Department of Brain Health.

Dr. Cummings leads the UNLV Clinical Trials Observatory, the world’s only research observatory devoted exclusively to analyzing the pipeline of Alzheimer's drugs in clinical trials to better inform drug development decisions. He also heads a biomarker observatory, which captures and categorizes emerging information on blood tests, brain scans, and digital devices related to Alzheimer's disease. 

Prior to joining UNLV in 2019, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, as well as two UCLA entities — the Mary S. Easton Center for Alzheimer’s Disease Research, and the Deane F. Johnson Center for Neurotherapeutics.

Named a “Rock Star of Science” by Gentleman’s Quarterly, Dr. Cummings — a fellow of the American Academy for the Advancement of Science — has published 43 books and more than 900 peer-reviewed articles on neuropsychiatry, Alzheimer’s disease, and clinical trials.

His numerous recognitions for his scientific and leadership contributions include the American Association of Geriatric Psychiatry’s Distinguished Scientist Award, Melvin R. Goodes Prize for Excellence in Drug Development from the Alzheimer's Drug Discovery Foundation, Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award, and the national Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award. In 2024, he was ranked by ScholarGPS as the world's top scholar for his lifetime contributions in the areas of dementia and drug development.

Education

  • Sc.D., Science, University of Wyoming
  • Neurology fellowship, Boston University School of Medicine
  • Neuropathology/Neuropsychiatry fellowship, National Hospital for Nervous Diseases, London
  • M.D., Medicine, University of Washington
  • B.S., Zoology/Philosophy, University of Wyoming

Search For Other Experts On

health & medicine, science & technology

Dr. Jeffrey L. Cummings In The News

Reuters
Details from two large trials of Novo Nordisk's NOVOb.CO GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wednesday, dashing remaining hopes that the widely used medication could help such patients.
Black Enterprise
When Herriot Tabuteau launched his drug development company, Axsome Therapeutics, in 2012, he decided to do things differently by focusing on treatments for brain disorders that are particularly challenging to develop. Now, he’s sitting on a $6 billion empire, according to Forbes.
BioPharmaDive
In the United States, 12% of adults have taken a glucagon-like peptide 1 (GLP-1) antagonist. The drugs aren’t just popular for weight loss; 62% of adults taking semaglutide or other GLP-1 drugs take them for chronic conditions, such as diabetes and heart disease — and dementia could be added to that list.
K.V.V.U. T.V. Fox 5
A new report offers hope for more than 57 million people suffering from dementia. The report, released by the Kirk Kerkorian School of Medicine at UNLV, looks at dozens of promising drug trials that could one day help find a cure for the disease.

Articles Featuring Dr. Jeffrey L. Cummings

From left to right: Aditi Singh, MD; Kate Martin, MD; Kavita Batra, PhD; and Deborah Kuhls, MD
Research | September 2, 2025

The medical school is dedicated to expanding its research curriculum, shaping the future of graduate medical education (GME).